ALCiS Health Inc., a consumer health company specializing in pain relief and body therapy products that utilize unique drug delivery technologies, announced the availability of ALCiS Daily Relief, a topical pain cream engineered to provide fast relief from muscle and joint pain, including that associated with arthritis, backache, strains, sprains and bruises.
A promising new drug candidate that may be effective against both actively dividing and slow-growing Mycobacterium tuberculosis (M. tb) has begun testing in humans, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced today. The novel antibiotic, PA-824, may shorten the time needed to treat tuberculosis (TB), a contagious disease that claims approximately two million lives worldwide each year. In partnership with the non-profit New York-based Global Alliance for TB Drug Development (TB Alliance), NIAID contributed to the drug candidate?s preclinical safety and efficacy testing in animal models. Now, a clinical trial to assess PA-824?s safety, sponsored by the TB Alliance, has opened at a medical clinic in Lincoln, NE.
New research under the direction of Paul Khavari, MD, PhD, professor in the Program in Epithelial Biology at the Stanford University School of Medicine and chief of the dermatology service at the Veterans Affairs Palo Alto Healthcare System, shows a novel and more effective way of testing which mutations cause cancer and which are mere research distractions. The work is published in the June issue of Nature Genetics.
A study found rituximab to be a safe and effective treatment for rheumatoid arthritis. The U.K. study, which included 465 men and women who had had arthritis for about 10 years, examined the effects of two doses of the drug.
The cancer drug rituximab may benefit lupus patients with central nervous system (CNS) complications, according to a new U.S. study.
Behavioral techniques that are known to improve sleep in non-demented institutionalized older adults may benefit patients with Alzheimer’s disease who have nighttime insomnia, according to the findings of a small study published in the Journal of the American Geriatrics Society.
Diabetic retinopathy has been found in nearly 8 percent of pre-diabetic participants in the Diabetes Prevention Program (DPP), according to a report presented today at the American Diabetes Association’s 65th Annual Scientific Sessions. Diabetic retinopathy, which can lead to vision loss, was also seen in 12 percent of participants with type 2 diabetes who developed diabetes during the DPP. No other long-term study has evaluated retinopathy in a population so carefully examined for the presence or development of type 2 diabetes.
A significantly lower risk of heart disease can now be added to the list of proven long-term benefits of tight glucose control in people with type 1 diabetes. Researchers announced this finding today at the annual scientific meeting of the American Diabetes Association after analyzing cardiovascular (CVD) events such as heart attack, stroke, and angina in patients who took part in the Diabetes Control and Complications Trial (DCCT) years ago.
An experimental pill that controls blood fats as well as blood sugar could be a better treatment for diabetics with high cholesterol even though side effects may be worse than current drugs, researchers said.
A hand-held imaging device designed for use at home appears effective in detecting breast cancer in its early stages, according to a University of Pennsylvania researcher who hopes the device might be available commercially to women in a year or two.